Pulmonary hypertension associated with benfluorex exposure

被引：59

作者：

Savale, Laurent ^{[1
,2
,3
]}

Chaumais, Marie-Camille ^{[1
,3
,4
]}

Cottin, Vincent ^{[5
]}

Bergot, Emmanuel ^{[6
]}

Frachon, Irene ^{[7
]}

Prevot, Gregoire ^{[8
]}

Pison, Christophe ^{[9
,10
]}

Dromer, Claire ^{[11
]}

Poubeau, Patrice ^{[12
]}

Lamblin, Nicolas ^{[13
]}

Habib, Gilbert ^{[14
]}

Reynaud-Gaubert, Martine ^{[15
]}

Bourdin, Arnaud ^{[16
]}

Sanchez, Olivier ^{[17
,18
]}

Tubert-Bitter, Pascale ^{[19
,20
]}

Jais, Xavier ^{[1
,2
,3
]}

Montani, David ^{[1
,2
,3
]}

Sitbon, Olivier ^{[1
,2
,3
]}

Simonneau, Gerald ^{[1
,2
,3
]}

Humbert, Marc ^{[1
,2
,3
]}

机构：

[1] Univ Paris Sud, Fac Med, F-94275 Le Kremlin Bicetre, France

[2] Hop Bicetre, AP HP, Ctr Reference Hypertens Pulm Severe, Serv Pneumol & Soins Intensifs, Le Kremlin Bicetre, France

[3] Ctr Chirurg Marie Lannelongue, INSERM, Hypertens Arterielle Pulm Physiopathol & Innovat, Le Plessis Robinson, France

[4] Hop Antoine Beclere, AP HP, Serv Pharm, Clamart, France

[5] Univ Lyon 1, Hop Louis Pradel, Serv Pneumol, HCL,Ctr Reference Malad Pulm Rares, F-69365 Lyon, France

[6] Ctr Hosp Univ, Serv Pneumol, Caen, France

[7] CHU Cavale Blanche, Grp HTAP Bretagne Occidentale, Dept Med Interne & Pneumol, EA GETBO 3878,IFR 148, Brest, France

[8] CHU, Hop Larrey, Serv Pneumol, Toulouse, France

[9] CHU Grenoble, Dept Cancerol, F-38043 Grenoble, France

[10] Univ Grenoble 1, Inserm 1055, Grenoble, France

[11] CHU, Hop Haut Levesque, Serv Chirurg Thorac, Bordeaux, France

[12] GHSR, Serv Malad Infect, St Pierre, Reunion, France

[13] CHRU, Hop Cardiol, Serv Cardiol, Lille, France

[14] CHU, Hop la Timone, Serv Cardiol, Marseille, France

[15] Univ Mediterranee, CHU Nord, AP HM, Serv Pneumol, Marseille, France

[16] CHU, Hop Arnaud de Villeneuve, Serv Malad Resp, Montpellier, France

[17] Univ Paris 05, Paris, France

[18] Univ Paris 05, Hop Europeen Georges Pompidou, APHP, Serv Pneumol & Soins Intensifs, Paris, France

[19] INSERM, U1018, CESP Ctr Rech Epidemiol & Sante Populat, Equipe Biostat, F-94807 Villejuif, France

[20] Univ Paris 11, UMRS 1018, F-94807 Villejuif, France

来源：

EUROPEAN RESPIRATORY JOURNAL | 2012年 / 40卷 / 05期

关键词：

Anorectic agents; benfluorex; fenfluramine derivates; pulmonary hypertension; valvular heart disease; VALVULAR HEART-DISEASE; ARTERIAL-HYPERTENSION; ANOREXIGEN AMINOREX; VASCULAR ORIGIN; FENFLURAMINE; ARTERIOPATHY; GUIDELINES; MUTATIONS; EPIDEMIC; LESSONS;

D O I：

10.1183/09031936.00188611

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Benfluorex was marketed in France until 2009, despite its similar pharmacological properties with fenfluramine and its derivatives known to be a cause of pulmonary arterial hypertension (PAH). The aim of this study is to report clinical and haemodynamic characteristics for patients suffering from pulmonary hypertension (PH) associated with benfluorex exposure that had been identified by the French PAH Network. 85 cases of PH associated with benfluorex exposure were identified by the French PAH Network from June 1999 to March 2011. Of these, 70 patients had confirmed pre-capillary PH. The median duration of exposure was 30 months, with a median of 108 months between start of exposure and diagnosis of the pulmonary vascular disease. 33% of all patients also had prior exposure to fenfluramine or dexfenfluramine, and an additional risk factor for PH was identified in 20 (30%) out of 70 patients with pre-capillary PH. A quarter of patients in this current series showed coexisting PH and mild-to-moderate cardiac valve involvement. The results of our study, together with the accumulated data regarding the known toxic effects of fenfluramine and dexfenfluramine, strongly suggest that benfluorex exposure is a potent trigger for PAH.

引用

页码：1164 / 1172

页数：9

共 34 条

[1] Appetite-suppressant drugs and the risk of primary pulmonary hypertension [J].

Abenhaim, L ;

Moride, Y ;

Brenot, F ;

Rich, S ;

Benichou, J ;

Kurz, X ;

Higenbottam, T ;

Oakley, C ;

Wouters, E ;

Aubier, M ;

Simonneau, G ;

Begaud, B .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (09) :609-616

[2]

ANSM. Cnamts, 2010, CNAMTS NOT COMPL DES

[3] Pulmonary Arterial Hypertension and Benfluorex: 5 Case Reports [J].

Bondon-Guitton, Emmanuelle ;

Prevot, Gregoire ;

Didier, Alain ;

Montastruc, Jean-Louis .

THERAPIE, 2011, 66 (02) :135-138

[4] Fenfluramine-like cardiovascular side-effects of benfluorex [J].

Boutet, K. ;

Frachon, I. ;

Jobic, Y. ;

Gut-Gobert, C. ;

Leroyer, C. ;

Carlhant-Kowalski, D. ;

Sitbon, O. ;

Simonneau, G. ;

Humbert, M. .

EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (03) :684-688

[5]

BRENOT F, 1993, BRIT HEART J, V70, P537

[6] Valvular heart disease associated with fenfluramine-phentermine [J].

Connolly, HM ;

Crary, JL ;

McGoon, MD ;

Hensrud, DD ;

Edwards, BS ;

Edwards, WD ;

Schaff, HV .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (09) :581-588

[7] Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene [J].

Deng, ZM ;

Morse, JH ;

Slager, SL ;

Cuervo, N ;

Moore, KJ ;

Venetos, G ;

Kalachikov, S ;

Cayanis, E ;

Fischer, SG ;

Barst, RJ ;

Hodge, SE ;

Knowles, JA .

AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (03) :737-744

[8] Echocardiographic Evidence for Valvular Toxicity of Benfluorex: A Double-Blind Randomised Trial in Patients with Type 2 Diabetes Mellitus [J].

Derumeaux, Genevieve ;

Ernande, Laura ;

Serusclat, Andre ;

Servan, Evelyne ;

Bruckert, Eric ;

Rousset, Hugues ;

Senn, Stephen ;

Van Gaal, Luc ;

Picandet, Brigitte ;

Gavini, Francois ;

Moulin, Philippe .

PLOS ONE, 2012, 7 (06)

[9] PULMONARY-HYPERTENSION AND FENFLURAMINE [J].

DOUGLAS, JG ;

MUNRO, JF ;

KITCHIN, AH ;

MUIR, AL ;

PROUDFOOT, AT .

BMJ-BRITISH MEDICAL JOURNAL, 1981, 283 (6296) :881-883

[10] Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis [J].

Eddahibi, S ;

Adnot, S .

RESPIRATORY RESEARCH, 2001, 3 (01)

← 1 2 3 4 →